Infliximab rescue therapy in acute severe ulcerative colitis: more does not equal better.

Lancet Gastroenterol Hepatol

Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi 110029, India. Electronic address:

Published: November 2024

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2468-1253(24)00229-2DOI Listing

Publication Analysis

Top Keywords

infliximab rescue
4
rescue therapy
4
therapy acute
4
acute severe
4
severe ulcerative
4
ulcerative colitis
4
colitis equal
4
equal better
4
infliximab
1
therapy
1

Similar Publications

Acute severe ulcerative colitis (ASUC) in pregnancy poses a clinical challenge with significant risk to both mother and fetus. Anti-TNF alpha therapy is known to be safe in pregnancy, however, data surrounding outcomes in ASUC is limited. In this report, we present the case of a pregnant patient of 10 weeks' gestation with ASUC successfully managed with intensified and accelerated infliximab therapy for a total dose of 35 mg/kg during a single admission.

View Article and Find Full Text PDF

Recent Advances in the Management of Acute Severe Ulcerative Colitis.

J Clin Med

December 2024

Leeds Gastroenterology Institute, Leeds Teaching Hospitals NHS Trust, St James University Hospital, Bexley Wing, Beckett Street, Leeds LS9 7TF, UK.

Acute severe ulcerative colitis is a medical emergency requiring inpatient treatment with intravenous steroids. Approximately one-third of patients do not respond to steroids sufficiently and require medical rescue therapy. Infliximab and cyclosporine are equally effective rescue agents, though infliximab is often preferred by clinicians for ease of use and greater familiarity.

View Article and Find Full Text PDF

Corticosteroids combined with infliximab vs. corticosteroids sequential infliximab for acute severe ulcerative colitis with mucosal deficiency: a retrospective study.

Front Med (Lausanne)

November 2024

State Key Laboratory of Cancer Biology, National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases, Air Force Military Medical University, Xi'an, China.

Article Synopsis
  • Mucosal deficiency in patients with acute severe ulcerative colitis (ASUC) poses significant treatment challenges, traditionally managed with intravenous corticosteroids and rescue therapy using infliximab.
  • A retrospective study involving 43 patients found that combining corticosteroids with infliximab resulted in higher endoscopic improvement and durable clinical remission rates compared to a sequential treatment approach.
  • The combination therapy was identified as a strong predictor of better outcomes, suggesting it may be a more effective first-line treatment for those with ASUC and mucosal deficiency, warranting further large-scale studies.
View Article and Find Full Text PDF

An Update on Kawasaki Disease.

Curr Rheumatol Rep

December 2024

Division of Rheumatology, Department of Pediatrics, The Warren Alpert Medical School of Brown University, Providence, RI, USA.

Purpose: To summarize advances in research on the epidemiology, pathogenesis, diagnosis, and treatment of Kawasaki Disease (KD), a systemic inflammatory illness of unknown etiology that affects children globally.

Recent Findings: The epidemiology of KD was affected by the COVID-19 pandemic and advances in molecular immunology and machine learning have enabled research into its pathogenesis. There is ongoing research into agents that can be used to intensify initial treatment and accumulating evidence supporting the use of certain rescue regimens for refractory disease over others.

View Article and Find Full Text PDF
Article Synopsis
  • Acute severe ulcerative colitis (ASUC) affects about 25% of ulcerative colitis patients and carries risks of colectomy and higher mortality rates; steroid treatment works for only 67% of patients, indicating a need for alternative therapies, particularly in the Vietnamese context where data is limited.
  • In a study conducted with 17 patients at a Ho Chi Minh City hospital from January 2021 to June 2023, most participants were middle-aged males, and over half had a prior ulcerative colitis diagnosis; steroid treatment had a 64.7% success rate, with some needing alternative medications like infliximab or tofacitinib.
  • The findings suggest corticosteroids are effective for initial ASUC treatment,
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!